FindTrial
Sign In

Clinical Application Research of Autologous Double Activation Targeted Immune System (NKg2d - CTL)

Clinical Application Research of Autologous Double Activation Targeted Immune System (NKg2d - CTL)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-16008772
Enrollment
Unknown
Registered
2016-07-03
Start date
2016-07-04
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Virus infection and malignant tumors

Interventions

Case series:Autologous Double Activation Targeted Immune System (NKg2d - CTL)

Sponsors

Shenzhen dragon hospital, medical center of cancer prevention and control precision
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Received the intervention treatment such as surgery, radiotherapy, chemotherapy, tumor basic control, life can provide for oneself; 2. there is risk of recurrence, low immunity, tumor load is small; 3. lifetime is more than 3 months; 4. with breast cancer, kidney cancer, liver cancer, lung cancer, gastric cancer, colorectal cancer, Patients with chronic hepatitis b and HPV infection.

Exclusion criteria

Exclusion criteria: 1. The T cell source malignant tumor; 2. Never received standard treatment; 3. Autoimmune diseases;

Design outcomes

Primary

MeasureTime frame
overall survival;Viruses copy number;—

Countries

China

Contacts

Public ContactShuangnian Zhou

Shenzhen Dragon Hospital, Medical Center of Cancer Prevention and Control Precision

snzhou@kkicpc.com+86 13316993208

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026